Molecular perspective on targeted therapy in breast cancer: a review of current status

Basit Öğe Kaydı
dc.authoridAvci, Cigir Biray/0000-0001-8251-4520
dc.authorscopusid57804485600
dc.authorscopusid57212299393
dc.authorwosidBiray Avcı, Cigir/GWV-1665-2022
dc.contributor.authorDemir Cetinkaya, Busra
dc.contributor.authorBiray Avci, Cigir
dc.date.accessioned2023-01-12T19:51:22Z
dc.date.available2023-01-12T19:51:22Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractBreast cancer is categorized at the molecular level according to the status of certain hormone and growth factor receptors, and this classification forms the basis of current diagnosis and treatment. The development of resistance to treatment and recurrence of the disease have led researchers to develop new therapies. In recent years, most of the research in the field of oncology has focused on the development of targeted therapies, which are treatment methods developed directly against molecular abnormalities. Promising advances have been made in clinical trials investigating the effect of these new treatment modalities and their combinations with existing therapeutic treatments in the treatment of breast cancer. Monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates, PI3K/Akt/mTOR pathway inhibitors, cyclin-dependent kinase 4/6 inhibitors, anti-angiogenic drugs, PARP inhibitors are among the targeted therapies used in breast cancer treatment. In this review, we aim to present a molecular view of recently approved target agents used in breast cancer.en_US
dc.identifier.doi10.1007/s12032-022-01749-1
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue10en_US
dc.identifier.pmid35834030en_US
dc.identifier.scopus2-s2.0-85134230115en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-022-01749-1
dc.identifier.urihttps://hdl.handle.net/11454/76264
dc.identifier.volume39en_US
dc.identifier.wosWOS:000825423600005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast canceren_US
dc.subjectTargeted therapyen_US
dc.subjectPI3Ken_US
dc.subjectAkten_US
dc.subjectmTOR pathway inhibitorsen_US
dc.subjectCDK4en_US
dc.subject6 inhibitorsen_US
dc.subjectPARP inhibitorsen_US
dc.subjectPi3k/Akt/Mtor Pathwayen_US
dc.subjectTrastuzumaben_US
dc.subjectManagementen_US
dc.subjectRibocicliben_US
dc.subjectLapatiniben_US
dc.subjectNeratiniben_US
dc.subjectRadiotherapyen_US
dc.subjectPalbocicliben_US
dc.subjectInhibitorsen_US
dc.subjectBlockadeen_US
dc.titleMolecular perspective on targeted therapy in breast cancer: a review of current statusen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu